Overview

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive pulmonary disease (COPD)
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim